Prevention of postmenopausal osteoporosis. Part 1: Identification of patients at risk and nonhormone preventive measures

被引:0
|
作者
Birkhaeuser, M. [1 ]
机构
[1] Univ Bern, Bern, Switzerland
来源
GYNAKOLOGISCHE ENDOKRINOLOGIE | 2013年 / 11卷 / 02期
关键词
Vitamin D; Calcium; Physical exercise; Risk factors; Fracture risk;
D O I
10.1007/s10304-013-0550-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Osteoporosis is one of the most frequent and cost-intensive diseases. In women aged >50 years and in postmenopausal women of all ages suffering from malnutrition or having an insufficient exposition to sunlight leading to low serum vitamin D levels, an adequate calcium intake, a sufficiently high vitamin D supplementation increasing with age and a sufficient protein intake (minimally 1 g/kg body weight protein per day) are essential for primary prevention of osteoporotic fractures. Vitamin D supplementation. Vitamin D prevents fractures through two mechanisms. Vitamin D has a positive effect on bone metabolism, and vitamin D increases muscle strength, resulting in a decreased risk of falls. Some sources recommend a vitamin D intake of 800-1000 IU/day. However, others suggest 1500-2000 IU/day vitamin D for adults aged >19 years. In the elderly having a high fracture risk, up to 2000 IU vitamin D/day is recommended. Calcium supplements. The preventive effect of vitamin D implies a sufficient, but not excessive daily calcium intake. To prevent osteoporotic fractures, a preferentially alimentary calcium supplementation of 1000-1200 mg/day calcium is recommended. The efficiency and safety of an adequate calcium and vitamin D supplementation has been proven. In particular, in studies observing the calcium intake limits defined above, no increased cardiovascular risk was observed. Uncontrolled additional calcium intake is not indicated. General measures. General prevention includes regular physical exercise (including strength training) combined with equilibrium training to prevent falls. Risk factors such as cigarette smoking, excessive alcohol intake and-if possible-the intake of drugs having a negative impact on bone metabolism (e.g., glucocorticoids, antiepileptics, suppressive thyroid hormone therapy) should be avoided. General preventive measures can be recommended without specific diagnostic investigations. Each therapeutic decision has to be preceded by an appropriate investigation for osteoporosis and prevalent fractures
引用
收藏
页码:129 / 136
页数:8
相关论文
共 50 条
  • [41] Vertebral Fracture Identification as Part of a Comprehensive Risk Assessment in Patients with Osteoporosis
    John T. Schousboe
    Current Osteoporosis Reports, 2018, 16 : 573 - 583
  • [42] Vertebral Fracture Identification as Part of a Comprehensive Risk Assessment in Patients with Osteoporosis
    Schousboe, John T.
    CURRENT OSTEOPOROSIS REPORTS, 2018, 16 (05) : 573 - 583
  • [43] Predictive factors for changes in spine deformity in relation to quality of life in patients with postmenopausal osteoporosis.
    Scholz, M
    Lazarescu, AD
    Pospeschill, M
    Makosch, S
    Hass, K
    Begerow, B
    Pfeifer, M
    Schlotthauer, T
    Pollaehne, W
    Minne, HW
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : F556 - F556
  • [44] Data driven approach to create a clinical algorithm for identification of female RA patients at high risk of osteoporosis.
    Kvien, TK
    Uhlig, T
    Haugeberg, G
    Falch, JA
    Halse, JI
    Lems, WF
    Dijkmans, BAC
    Woolf, AD
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S305 - S305
  • [45] Performance of COLIA1, Vdr and Er polymorphism to identify postmenopausal women with osteoporosis.
    Muñoz-Torres, ME
    Mezquita-Raya, P
    Lopez-Rodriguez, F
    Luna, J
    Ouesada, J
    Luque-Recio, F
    Escobar-Jimenez, F
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S477 - S477
  • [46] Effects of low dosage of 1-Alpha-OH-D3 in the postmenopausal osteoporosis.
    Dreval, AV
    Marchenkova, LA
    Tischenina, RS
    Minchenko, BI
    Onprienko, GA
    Shumsky, VI
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S285 - S285
  • [47] OSTEOPOROSIS IN THE ELDERLY: IDENTIFICATION OF RISK FACTORS FOR PREVENTION
    Sanchez-de las Matas, R.
    Fernandez-Garcia, G.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S548 - S548
  • [48] NUMBER NEEDED TO TREAT FOR PREVENTION OF FRACTURES IN PATIENTS WITH SEVERE OSTEOPOROSIS. SYSTEMIC REVIEW
    Alfaro, J.
    Manuel
    Gamboa, R.
    Acevedo, E.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S8 - S8
  • [49] Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women receiving treatment for prevention or treatment of osteoporosis.
    Palacios, S
    Farias, ML
    Luebbert, H
    Gomez, G
    Yabur, JA
    Quail, DC
    Turbi, C
    Kayath, MJ
    Almeida, MJ
    Moennig, E
    Nickelsen, TN
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S272 - S272
  • [50] Risedronate for the prevention and treatment of postmenopausal osteoporosis. (Withdrawn Paper. 2003 art no. CD004523)
    Cranney, A
    Adachi, JD
    Guyatt, G
    Papaioannou, A
    Robinson, VA
    Shea, BJ
    Tugwell, P
    Waldegger, LM
    Weaver, B
    Wells, G
    Zytaruk, N
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):